Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.
| Website | http://www.encodia.com |
| Revenue | $9.7 million |
| Employees | 19 (19 on RocketReach) |
| Founded | 2015 |
| Address | 5785 Oberlin Drive, San Diego, California 92121, US |
| Technologies |
JavaScript
,
HTML
,
Google Analytics
+26 more
(view full list)
|
| Industry | Biotechnology, Other Pharmaceuticals and Biotechnology |
| Keywords | Protein Sequencing, Proteomic Analysis, Next Generation Sequencing, Peptide Sequencing, Protein Identification, Protein Analysis, Protein Research, Biotechnology, Biotechnology Platform, Genomics, Life Sciences, Innovative Technology, Dna Sequencing, Bioinformatics, Omics, Molecular Biology |
| Competitors | Thermo Fisher Scientific, Agilent Technologies, Illumina, Bio-Rad Laboratories, QIAGEN, GeneDx, Twist Bioscience, Oxford Nanopore Technologies, PacBio, 23andMe +35 more (view full list) |
Looking for a particular Encodia employee's phone or email?
The Encodia annual revenue was $9.7 million in 2026.
Angela Blum is the Director, Head of Chemistry of Encodia.
19 people are employed at Encodia.
Encodia is based in San Diego, California.